FRANKLIN LAKES, N.J.,
Feb. 13, 2020 /PRNewswire/ -- BD
(Becton, Dickinson and Company) (NYSE: BDX), a leading global
medical technology company, today announced a new, $6 million contract with the Fleming Fund, a
U.K. aid program that helps low- and middle-income countries around
the world tackle antimicrobial resistance (AMR).
Through this agreement, BD will provide diagnostic equipment and
informatics solutions that help aid in the diagnosis of infections
and guide physicians to provide appropriate antimicrobial
prescribing and use.
Specifically, BD will equip more than 70 labs with solutions
that include the BD BACTEC™ FX40 Blood Culture System designed for
the rapid detection of bacteria and fungi in clinical specimens;
blood and blood products; the BD Phoenix™ M50 Automated
Microbiology System for the rapid identification (ID) and
Antimicrobial Susceptibility Testing (AST) of clinically
significant bacteria; and the BD™ Bruker MALDI Biotyper™ System for
the rapid identification (ID) of microorganisms. For microbiology
data management and informatics solutions, BD will be providing the
BD EpiCenter™ Microbiology Data Management System and the BD
Synapsys™ Microbiology Informatics Solution.
The program is funded by the U.K. Department of Health and
Social Care and delivered by Mott MacDonald, the Fleming Fund
Grant Management Agent for Fellowships, Regional and Country
Grants.
The Fleming Fund works to support 24 countries in the
development of AMR surveillance systems, using The World Health
Organization's "One Health" approach. One of the core
activities for the Fleming Fund country grant program is to
strengthen clinical bacteriology laboratories in order to identify
and perform antimicrobial susceptibility testing (AST) on priority
pathogens.
Over the last several years, BD has made significant global
efforts and investments to combat AMR in the areas of
infection prevention, diagnostics, and surveillance and reporting,
earning the company recognition on Fortune's Change the
World list in 2019 for its third time. BD Integrated
Diagnostic Solutions (IDS) has a portfolio of microbiology
solutions designed to support clinical microbiology decision making
with quality and accurate diagnostics. These integrated, end-to-end
offerings help enhance and streamline workflows, reduce time to
result and may help to improve clinical, operational and financial
outcomes.
"BD will be providing product solutions to 19 low-resource
countries, aiding labs in detecting drug resistant bacterial
infections and helping to improve laboratory practices. This
expansive measure helps to further combat the global threat of AMR
and is credit to the Fleming Fund's significant advancement of
laboratories in regions that are most vulnerable," said Dave Hickey, WW President, BD Life Sciences -
Integrated Diagnostic Solutions.
"It's a pleasure to partner with BD to tackle antimicrobial
resistance by strengthening and equipping laboratories with new
technology. As the Management Agent for the Fleming Fund we are
passionate about building effective and sustainable partnerships so
that governments can take action against drug resistance for a
healthier world," said Steve Wilson,
Fleming Fund Programme Director at Mott MacDonald.
For more information about BD's efforts to combat AMR, including
partnerships with the Foundation for New Innovative
Diagnostics and London School of Hygiene and Tropical
Medicine to support diagnostic testing, visit the company news
blog.
About BD
BD is one of the largest global medical technology companies in the
world and is advancing the world of health by improving medical
discovery, diagnostics and the delivery of care. The
company develops innovative technology, services and
solutions that help advance both clinical therapy for patients and
clinical process for health care providers. BD and its 65,000
employees have a passion and commitment to help improve patient
outcomes, improve the safety and efficiency of clinicians' care
delivery process, enable laboratory scientists
to accurately detect disease and advance
researchers' capabilities to develop the next generation of
diagnostics and therapeutics. BD has a presence in virtually every
country and partners with organizations around the world to address
some of the most challenging global health issues. BD helps
customers enhance outcomes, lower costs, increase
efficiencies, improve safety and expand access to health
care. For more information on BD, please visit
bd.com.
About the Fleming Fund
The Fleming Fund is a £265
million UK aid investment to tackle antimicrobial resistance in
low- and middle-income countries around the world. The program is
managed by the UK Department of Health and Social Care, in
partnership with Mott MacDonald, the Fleming Fund Grant Management
Agent.
Contacts:
Jessica
Offerjost
|
Monique N.
Dolecki
|
BD Public
Relations
|
BD Investor
Relations
|
201-847-5297
|
201.847.5378
|
jessica.offerjost@bd.com
|
Monique_Dolecki@bd.com
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/bd-collaborates-with-fleming-fund-to-help-combat-threat-of-antimicrobial-resistance-in-asia-and-sub-saharan-africa-301003649.html
SOURCE BD (Becton, Dickinson and Company)